Invion Advances Skin Cancer Trial After Promising Early Results
IVX: $0.037 +0.00% · MC: $4M
Invion says preliminary results from 14 patient readouts in its completed Phase I non-melanoma skin cancer trial showed no treatment-related adverse events or dose-limiting toxicities and a 79% disease control rate, supporting progression to Phase II; final results await 12-month follow-up and independent audit. Two multi-year financing arrangements are expected to cover up to approximately 85% of current and future clinical development costs, while a new preclinical collaboration will test Photosoft with Percheron Therapeutics’ immunotherapy. Quarter-end cash was approximately $512,000, down from approximately $592,000 in the previous quarter.

Comments